Literature DB >> 22278326

Human papillomavirus antibody reference reagents for use in postvaccination surveillance serology.

Sara L Bissett1, Dianna Wilkinson, Kate I Tettmar, Nicky Jones, Elaine Stanford, Gitika Panicker, Helena Faust, Ray Borrow, Kate Soldan, Elizabeth R Unger, Joakim Dillner, Philip Minor, Simon Beddows.   

Abstract

Suitably controlled serosurveillance surveys are essential for evaluating human papillomavirus (HPV) immunization programs. A panel of plasma samples from 18-year-old females was assembled, the majority of the samples being from recipients of the bivalent HPV vaccine. Antibody specificities were evaluated by three independent laboratories, and 3 pools that displayed no antibodies to any HPV type tested or intermediate or high levels of antibody to HPV16, HPV18, HPV31, and HPV45 were created. These pools will be useful as control reagents for HPV serology.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22278326      PMCID： PMC3294620          DOI： 10.1128/CVI.05641-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  19 in total

Review 1.  Vaccines to prevent infections by oncoviruses.

Authors:  John T Schiller; Douglas R Lowy
Journal:  Annu Rev Microbiol       Date:  2010       Impact factor: 15.500

2.  Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication.

Authors:  Ni Li; Silvia Franceschi; Rebecca Howell-Jones; Peter J F Snijders; Gary M Clifford
Journal:  Int J Cancer       Date:  2011-02-15       Impact factor: 7.396

Review 3.  Vaccines: correlates of vaccine-induced immunity.

Authors:  Stanley A Plotkin
Journal:  Clin Infect Dis       Date:  2008-08-01       Impact factor: 9.079

4.  Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18.

Authors:  Dennis Dias; Jeff Van Doren; Sonela Schlottmann; Sheri Kelly; Derek Puchalski; Wanda Ruiz; Patricia Boerckel; Joseph Kessler; Joseph M Antonello; Tina Green; Martha Brown; Judith Smith; Narendra Chirmule; Eliav Barr; Kathrin U Jansen; Mark T Esser
Journal:  Clin Diagn Lab Immunol       Date:  2005-08

5.  The first international standard for antibodies to HPV 16.

Authors:  Morag Ferguson; Dianna E Wilkinson; Alan Heath; Paul Matejtschuk
Journal:  Vaccine       Date:  2011-07-19       Impact factor: 3.641

6.  Generation of HPV pseudovirions using transfection and their use in neutralization assays.

Authors:  Christopher B Buck; Diana V Pastrana; Douglas R Lowy; John T Schiller
Journal:  Methods Mol Med       Date:  2005

7.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.

Authors:  Diane M Harper; Eduardo L Franco; Cosette Wheeler; Daron G Ferris; David Jenkins; Anne Schuind; Toufik Zahaf; Bruce Innis; Paulo Naud; Newton S De Carvalho; Cecilia M Roteli-Martins; Julio Teixeira; Mark M Blatter; Abner P Korn; Wim Quint; Gary Dubin
Journal:  Lancet       Date:  2004 Nov 13-19       Impact factor: 79.321

8.  Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera.

Authors:  Eve Draper; Sara L Bissett; Rebecca Howell-Jones; Debbie Edwards; Graham Munslow; Kate Soldan; Simon Beddows
Journal:  Vaccine       Date:  2011-09-21       Impact factor: 3.641

9.  Seroprevalence of 34 human papillomavirus types in the German general population.

Authors:  Kristina M Michael; Tim Waterboer; Peter Sehr; Annette Rother; Ulrich Reidel; Heiner Boeing; Ignacio G Bravo; Jörg Schlehofer; Barbara C Gärtner; Michael Pawlita
Journal:  PLoS Pathog       Date:  2008-06-20       Impact factor: 6.823

10.  Prevalence of human papillomavirus antibodies in young female subjects in England.

Authors:  M Jit; A Vyse; R Borrow; R Pebody; K Soldan; E Miller
Journal:  Br J Cancer       Date:  2007-08-28       Impact factor: 7.640
View more
  10 in total

1.  Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.

Authors:  Sara L Bissett; Anna Godi; Maxime J J Fleury; Antoine Touze; Clementina Cocuzza; Simon Beddows
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

2.  Comparisons of VLP-Based ELISA, Neutralization Assays with Native HPV, and Neutralization Assays with PsV in Detecting HPV Antibody Responses in HIV-Infected Women.

Authors:  Ping Du; Sarah Brendle; Janice Milici; Fabian Camacho; John Zurlo; Neil Christensen; Craig Meyers
Journal:  J AIDS Clin Res       Date:  2015-03

3.  Multiplex Human Papillomavirus L1L2 virus-like particle antibody binding assay.

Authors:  Kavita Panwar; Anna Godi; Clementina E Cocuzza; Nick Andrews; Jo Southern; Paul Turner; Elizabeth Miller; Simon Beddows
Journal:  MethodsX       Date:  2022-06-25

4.  A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.

Authors:  Eve Draper; Sara L Bissett; Rebecca Howell-Jones; Pauline Waight; Kate Soldan; Mark Jit; Nicholas Andrews; Elizabeth Miller; Simon Beddows
Journal:  PLoS One       Date:  2013-05-01       Impact factor: 3.240

5.  Contribution of Surface-Exposed Loops on the HPV16 Capsid to Antigenic Domains Recognized by Vaccine or Natural Infection Induced Neutralizing Antibodies.

Authors:  Anna Godi; Stuti Vaghadia; Clementina Cocuzza; Elizabeth Miller; Simon Beddows
Journal:  Microbiol Spectr       Date:  2022-04-27

6.  The DE and FG loops of the HPV major capsid protein contribute to the epitopes of vaccine-induced cross-neutralising antibodies.

Authors:  Sara L Bissett; Anna Godi; Simon Beddows
Journal:  Sci Rep       Date:  2016-12-22       Impact factor: 4.379

7.  Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development.

Authors:  Ligia A Pinto; Joakim Dillner; Simon Beddows; Elizabeth R Unger
Journal:  Vaccine       Date:  2018-02-01       Impact factor: 3.641

8.  The possible regions to design Human Papilloma Viruses vaccine in Iranian L1 protein.

Authors:  Behzad Dehghani; Zahra Hasanshahi; Tayebeh Hashempour; Mohamad Motamedifar
Journal:  Biologia (Bratisl)       Date:  2019-12-24       Impact factor: 1.350

9.  Evaluation of Dried Blood Spots and Oral Fluids as Alternatives to Serum for Human Papillomavirus Antibody Surveillance.

Authors:  Karly S Louie; Jama Dalel; Caroline Reuter; Sara L Bissett; Michelle Kleeman; Lesley Ashdown-Barr; Rawinder Banwait; Anna Godi; Peter Sasieni; Simon Beddows
Journal:  mSphere       Date:  2018-05-09       Impact factor: 4.389

10.  Persistence of Immunity When Using Different Human Papillomavirus Vaccination Schedules and Booster-Dose Effects 5 Years After Primary Vaccination.

Authors:  Eduardo Lazcano-Ponce; Leticia Torres-Ibarra; Aurelio Cruz-Valdez; Jorge Salmerón; Tonatiuh Barrientos-Gutiérrez; Javier Prado-Galbarro; Margaret Stanley; Nubia Muñoz; Rolando Herrero; Mauricio Hernández-Ávila
Journal:  J Infect Dis       Date:  2019-01-01       Impact factor: 5.226
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.